DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Read more about DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Read more about Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Clinical trial end points for high-grade glioma: the evolving landscape. Read more about Clinical trial end points for high-grade glioma: the evolving landscape.
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Read more about MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Read more about Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Read more about A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
Risk factors for oligodendroglial tumors: a pooled international study. Read more about Risk factors for oligodendroglial tumors: a pooled international study.
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Read more about Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Read more about Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Read more about Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.
